Eledon Pharmaceuticals (ELDN) Income from Continuing Operations (2013 - 2026)
Eledon Pharmaceuticals (ELDN) posted Income from Continuing Operations of 21281000.0 for Q1 2026, down 7.13% on a QoQ basis from 19865000.0 in Q3 2025, and down 12.28% year-over-year from 24259341.67 in Q1 2025.
Eledon Pharmaceuticals (ELDN) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Eledon Pharmaceuticals' Income from Continuing Operations history runs 14 years deep, the most recent figure standing at 21281000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 12.28% year-over-year to 21281000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 85726000.0 (down 7.28% YoY) and the FY2025 annual result came in at 45617000.0, down 26.07% from the prior year.
- Income from Continuing Operations was 21281000.0 for Q1 2026 at Eledon Pharmaceuticals, down from 19865000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 9247000.0 in Q2 2022 and bottomed at 58384000.0 in Q4 2022.
- A 5-year average of 18128625.0 and a median of 13430000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 563.0% — and 2023, when it surged 82.12%.
- Eledon Pharmaceuticals' Income from Continuing Operations stood at 58384000.0 in 2022, then jumped by 82.12% to 10437000.0 in 2023, then sank by 137.64% to 24802000.0 in 2024, then increased by 19.91% to 19865000.0 in 2025, then fell by 7.13% to 21281000.0 in 2026.
- Business Quant data shows ELDN's Income from Continuing Operations at 21281000.0 in Q1 2026, 19865000.0 in Q3 2025, and 25626000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | - |
| 3 | Akari Therapeutics | 1,023.69 Bn | 1,023.69 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 468.59 Bn | 463.80 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 123.01 Bn | 115.76 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.29 Bn | 61.53 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 63.33 Bn | 63.33 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.70 Bn | 50.52 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.79 Bn | 34.78 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Eledon Pharmaceuticals | 405.29 Mn | 405.29 Mn | - | -21.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.28 Mn |
| Sep 30, 2025 | -19.87 Mn |
| Jun 30, 2025 | -25.63 Mn |
| Mar 31, 2025 | -18.95 Mn |
| Dec 31, 2024 | -24.80 Mn |
| Sep 30, 2024 | -20.98 Mn |
| Jun 30, 2024 | -15.18 Mn |
| Mar 31, 2024 | -11.16 Mn |
| Dec 31, 2023 | -10.44 Mn |
| Sep 30, 2023 | -11.69 Mn |
| Jun 30, 2023 | -10.94 Mn |
| Mar 31, 2023 | -11.19 Mn |
| Dec 31, 2022 | -58.38 Mn |
| Sep 30, 2022 | -10.47 Mn |
| Jun 30, 2022 | -9.25 Mn |
| Mar 31, 2022 | -9.86 Mn |
| Dec 31, 2021 | -8.81 Mn |
| Sep 30, 2021 | -9.82 Mn |
| Jun 30, 2021 | -7.38 Mn |
| Mar 31, 2021 | -8.50 Mn |